Adaptive Biotechnologies (ADPT) Total Current Liabilities (2018 - 2026)

Adaptive Biotechnologies has disclosed Total Current Liabilities across 9 years of filings, most recently posting $87.7 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 4.81% year-over-year to $87.7 million; the TTM figure through Jun 2026 stood at $87.7 million (down 4.81% YoY), while the FY2025 annual figure was $89.9 million, down 8.3% from the prior year.
• Total Current Liabilities came in at $87.7 million for Q2 2026 at Adaptive Biotechnologies, up from $87.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $115.1 million in Q1 2022 to a low of $83.0 million in Q1 2024.
• Average Total Current Liabilities over 5 years is $94.0 million, with a median of $90.0 million recorded in 2023.
• Year-over-year, Total Current Liabilities fell 21.7% in 2023 and increased 11.4% in 2024.
• Over 5 years, Total Current Liabilities stood at $109.8 million in 2022, then dropped by 19.83% to $88.0 million in 2023, then climbed by 11.4% to $98.1 million in 2024, then fell by 8.3% to $89.9 million in 2025, then retreated by 2.45% to $87.7 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $87.7 million in Q2 2026, $87.0 million in Q1 2026, and $89.9 million in Q4 2025.